Effect of Modified LMB 89± Rituximab Regimen on Long-Term Benefits for Patients's with Burkitt Lymphoma / 中国实验血液学杂志
Journal of Experimental Hematology
; (6): 872-875, 2020.
Article
em Zh
| WPRIM
| ID: wpr-827193
Biblioteca responsável:
WPRO
ABSTRACT
OBJECTIVE@#To investigate the effect of modified LMB 89± rituximab regimen on long-term clinical benefit for patients with Burkitt lymphoma.@*METHODS@#Clinical data of 43 patients with Burkitt lymphoma were collected and retrospectively analyzed in the period from July 2006 to October 2017. Forty-three patients were divided into 2 groups, including Hyper-CVAD regimen, R-EPOCD regimen or VDCLP regimen treated group as control (20 patients) and modified regimen group with modified LMB 89±rituximab regimen (23 patients); the event-free survival (EFS) rate, overall survival (OS) rate, cumulative incidence of relapse (CIR), non-relapse mortality rate (NRM) and adverse reaction incidence of 2 groups were compared. At the same time, the efficacy analysis for patients of modified regimen group was performed according to age and using rituximab or no.@*RESULTS@#The EFS rate and OS rate of modified regimen group were significantly higher than those of control group (P<0.05). The CRR rate and NRM rate of modified regimen group were significantly lower than those of control group (P<0.05). The EFS rate and OS rate of patients for <40 years old were significantly higher than those of patients for ≥40 years old in modified regimen group (P<0.05). The EFS rate and OS rate of patients with rituximab were significantly higher than those of patients without rituximab in modified regimen group (P<0.05). There was no significant difference in the adverse reaction incidence between 2 groups (P>0.05).@*CONCLUSION@#Modified LMB 89± rituximab regimen in the treatment of patients with Burkitt lymphoma can efficiently prolong survival time and shows the better safety; and the remigen combined with rituximab is more helpful to improve the clinical prognosis and show the better clinical effects for the patients≤40 years old.
Texto completo:
1
Índice:
WPRIM
Assunto principal:
Protocolos de Quimioterapia Combinada Antineoplásica
/
Doxorrubicina
/
Metotrexato
/
Estudos Retrospectivos
/
Linfoma de Burkitt
/
Resultado do Tratamento
/
Intervalo Livre de Doença
/
Ciclofosfamida
/
Citarabina
/
Usos Terapêuticos
Tipo de estudo:
Observational_studies
Limite:
Adult
/
Humans
Idioma:
Zh
Revista:
Journal of Experimental Hematology
Ano de publicação:
2020
Tipo de documento:
Article